RAMPx
Risk-Adjusted-Market-Potential

The Problem: Over 50% of new products never achieve their pre-launch forecasts.

What's needed is a better way to consistently measure the strength of the value proposition of new products in development – which to advance, prioritization of spend, how to enhance evidence generation for optimum market adoption.

The Solution: RAMPx assesses the strength of a new product’s value proposition quickly and affordably.

Consistent metrics that measure all the drivers/inhibitors of new product adoption (rational, economic, emotional, and social)
Captures the views and perspectives of all relevant stakeholders
Provides a synthesized view and common framework across products/companies, as well as competitors
Can be used across all types of products so it can be applied across the internal portfolio/licensing
- RAMP Dx - Diagnostics
- RAMP Rx - Drugs and devices
- RAMP Tx - Therapeutics

RAMPx: A Critical Input Into Forecast Development and Potential Risks

Goal is to make the RAMPx score and process utilized and accepted across the pipeline and operating units

RAMPx: Assesses New Product Value in a Dynamic Environment

The RAMPx scores for a particular product provide an indicator of the dynamics that are likely to exist between stakeholders for any product. Examples: Product 1 would be patient driven. Product 2 is likely to encounter strong payer resistance and physicians are not likely to counter a step-edit or PA imposed by payers.